Literature DB >> 20594269

Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Takayuki Shiomi1, Vincent Lemaître, Jeanine D'Armiento, Yasunori Okada.   

Abstract

Cellular functions within tissues are strictly regulated by the tissue microenvironment which comprises extracellular matrix and extracellular matrix-deposited factors such as growth factors, cytokines and chemokines. These molecules are metabolized by matrix metalloproteinases (MMP), a disintegrin and metalloproteinases (ADAM) and ADAM with thrombospondin motifs (ADAMTS), which are members of the metzincin superfamily. They function in various pathological conditions of both neoplastic and non-neoplastic diseases by digesting different substrates under the control of tissue inhibitors of metalloproteinases (TIMP) and reversion-inducing, cysteine-rich protein with Kazal motifs (RECK). In neoplastic diseases MMP play a central role in cancer cell invasion and metastases, and ADAM are also important to cancer cell proliferation and progression through the metabolism of growth factors and their receptors. Numerous papers have described the involvement of these metalloproteinases in non-neoplastic diseases in nearly every organ. In contrast to the numerous review articles on their roles in cancer cell proliferation and progression, there are very few articles discussing non-neoplastic diseases. This review therefore will focus on the properties of MMP, ADAM and ADAMTS and their implications for non-neoplastic diseases of the cardiovascular system, respiratory system, central nervous system, digestive system, renal system, wound healing and infection, and joints and muscular system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20594269      PMCID: PMC3745773          DOI: 10.1111/j.1440-1827.2010.02547.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  176 in total

Review 1.  MT1-MMP: a potent modifier of pericellular microenvironment.

Authors:  Yoshifumi Itoh; Motoharu Seiki
Journal:  J Cell Physiol       Date:  2006-01       Impact factor: 6.384

2.  Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test.

Authors:  Kathryn Gogolin Ewens; Roberta Ann George; Kumar Sharma; Fuad N Ziyadeh; Richard S Spielman
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

3.  Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries.

Authors:  Jason L Johnson; Sarah J George; Andrew C Newby; Christopher L Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-12       Impact factor: 11.205

4.  Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques.

Authors:  Jun-O Deguchi; Elena Aikawa; Peter Libby; Jeffrey R Vachon; Masaki Inada; Stephen M Krane; Peter Whittaker; Masanori Aikawa
Journal:  Circulation       Date:  2005-10-17       Impact factor: 29.690

5.  Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy.

Authors:  Kyoichi Tashiro; Ichiro Koyanagi; Ikko Ohara; Takamichi Ito; Akemi Saitoh; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

6.  Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease.

Authors:  John C Adair; Julius Charlie; John E Dencoff; Jeffrey A Kaye; Joseph F Quinn; Richard M Camicioli; William G Stetler-Stevenson; Gary A Rosenberg
Journal:  Stroke       Date:  2004-04-22       Impact factor: 7.914

7.  Extracellular regulated kinase/mitogen activated protein kinase is up-regulated in pulmonary emphysema and mediates matrix metalloproteinase-1 induction by cigarette smoke.

Authors:  Becky A Mercer; Natalia Kolesnikova; Joshua Sonett; Jeanine D'Armiento
Journal:  J Biol Chem       Date:  2004-02-05       Impact factor: 5.157

8.  Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth.

Authors:  Aernout Luttun; Esther Lutgens; Ann Manderveld; Katleen Maris; Désiré Collen; Peter Carmeliet; Lieve Moons
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

9.  Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.

Authors:  Donglei Zhang; Menashe Bar-Eli; Sylvain Meloche; Pnina Brodt
Journal:  J Biol Chem       Date:  2004-03-01       Impact factor: 5.157

10.  Expression of ADAM15 in rheumatoid synovium: up-regulation by vascular endothelial growth factor and possible implications for angiogenesis.

Authors:  Koichiro Komiya; Hiroyuki Enomoto; Isao Inoki; Satoko Okazaki; Yoshinari Fujita; Eiji Ikeda; Eiko Ohuchi; Hideo Matsumoto; Yoshiaki Toyama; Yasunori Okada
Journal:  Arthritis Res Ther       Date:  2005-08-05       Impact factor: 5.156

View more
  86 in total

1.  Genetic variations in the ADAMTS12 gene are associated with schizophrenia in Puerto Rican patients of Spanish descent.

Authors:  Irina N Bespalova; Gary W Angelo; Ben P Ritter; Jason Hunter; Maria L Reyes-Rabanillo; Larry J Siever; Jeremy M Silverman
Journal:  Neuromolecular Med       Date:  2012-02-10       Impact factor: 3.843

2.  Inhibitory effects of EGb761 on the expression of matrix metalloproteinases (MMPs) and cartilage matrix destruction.

Authors:  Xuewen Wang; Xingshen Zhao; Shusen Tang
Journal:  Cell Stress Chaperones       Date:  2015-06-05       Impact factor: 3.667

3.  Controlled protein delivery based on enzyme-responsive nanocapsules.

Authors:  Jing Wen; Sean M Anderson; Juanjuan Du; Ming Yan; Jun Wang; Meiqing Shen; Yunfeng Lu; Tatiana Segura
Journal:  Adv Mater       Date:  2011-09-12       Impact factor: 30.849

Review 4.  Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration.

Authors:  Ninad Varkhede; Rupesh Bommana; Christian Schöneich; M Laird Forrest
Journal:  J Pharm Sci       Date:  2019-08-10       Impact factor: 3.534

5.  Ginsenoside Rb1 inhibits matrix metalloproteinase 13 through down-regulating Notch signaling pathway in osteoarthritis.

Authors:  Wei Wang; Li Zeng; Ze-ming Wang; Sihan Zhang; Xiao-Feng Rong; Rong-Heng Li
Journal:  Exp Biol Med (Maywood)       Date:  2015-06-09

6.  The Investigation of ADAMTS16 in Insulin-Induced Human Chondrosarcoma Cells.

Authors:  Ozlem Cakmak; Ismail Comertoglu; Ridvan Firat; Haci Kemal Erdemli; S Fatih Kursunlu; Sumeyya Akyol; Veli Ugurcu; Aynur Altuntas; Bahattin Adam; Kadir Demircan
Journal:  Cancer Biother Radiopharm       Date:  2015-08       Impact factor: 3.099

7.  Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer.

Authors:  Alexandra Mj Langers; Hein W Verspaget; Daniel W Hommes; Cornelis Fm Sier
Journal:  World J Gastrointest Oncol       Date:  2011-06-15

Review 8.  Osteoarthritis pathogenesis: a review of molecular mechanisms.

Authors:  Bingjiang Xia; Jushi Zhang; Songfeng Hu; Hongting Jin; Peijian Tong
Journal:  Calcif Tissue Int       Date:  2014-10-14       Impact factor: 4.333

9.  Activation of β-catenin signalling leads to temporomandibular joint defects.

Authors:  M Wang; S Li; W Xie; J Shen; H J Im; J D Holz; M Wang; T G Diekwisch; D Chen
Journal:  Eur Cell Mater       Date:  2014-10-23       Impact factor: 3.942

Review 10.  Invasion and metastasis of renal cell carcinoma.

Authors:  Shuji Mikami; Mototsugu Oya; Ryuichi Mizuno; Takeo Kosaka; Ken-ichi Katsube; Yasunori Okada
Journal:  Med Mol Morphol       Date:  2013-11-09       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.